# IMbrave151 (NCT04677504)

> A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

No report yet. It can be ordered.

- Drugs tested: atezolizumab plus bevacizumab
- Indication: untreated advanced biliary tract cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04677504
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Biliary Tract Cancer
- Interventions: Atezolizumab; Bevacizumab; Placebo; Cisplatin; Gemcitabine
- Enrollment: 162
- Primary outcome: Progression Free Survival (PFS)

## Indexed commentary on IMbrave151 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 28
- YouTube: 1
- Podcasts: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=imbrave151-nct04677504

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04677504", "email": "<work email>"}; the inbox owner confirms by the emailed link.